Storys zum Thema Chemie

Accord Healthcare

Accord Healthcare is granted marketing authorisation for IMULDOSA®, ustekinumab biosimilar to Stelara®

London (ots/PRNewswire) - - Accord announces that the European Commission (EC has granted marketing authorisation for Imuldosa® (development code: DMB-3115), a biosimilar to Stelara®, indicated for a range of immune medicated inflammatory diseases. - The EC approval follows a positive opinion issued on 19 October ...

Strides Pharma International AG

Strides Pharma Consolidates European Business-to-Business Operations in Switzerland

Grünenthal Group

Grünenthal and Averitas Pharma announce completion of recruitment for Phase III clinical trial with QUTENZA® in post-surgical neuropathic pain

Aachen, Germany/Morristown, N.J. (ots) - - The Phase III trial AV001 aims to evaluate QUTENZA® in post-surgical neuropathic pain (PSNP), a debilitating complication of surgery occurring after approximately 10 percent of all surgical procedures[1], thus affecting more than 3 million people with surgical procedures ...

Schweizerischer Nationalfonds / Fonds national suisse

She uses light to modify matter

Grünenthal Group

First participants enrolled in first-in-human Phase I clinical trial with nociceptin (NOP) receptor agonist

Aachen, Germany (ots) - Today, Grünenthal announced that the first participants have been enrolled in a first-in-human Phase I clinical trial for a nociceptin (NOP) receptor agonist. The trial will include 90 healthy volunteers and aims to demonstrate a favourable safety and tolerability profile and to confirm the ...

Epitomee Medical

Epitomee Medical to Present the Epitomee Breakthrough Oral Delivery Platform at PODD 2024 Conference

Caesarea, Israel (ots/PRNewswire) - Epitomee Medical Ltd. (TASE: EPIT) announces today that the company leadership intends to present Epitomee's Oral Delivery of Biologics Platform at the 14th Annual PODD Conference - Partnership Opportunities in Drug Delivery, taking place in Boston, MA, October 28-29, 2024. ...

Epitomee Medical

Epitomee Medical Announces FDA Clearance of its Capsule, Weight Management Device

Caesarea, Israel (ots/PRNewswire) - Epitomee's Ingestible Capsule, Offers a Safe and Effective Prescription Solution for Adults with BMI of 25-40 looking for Alternative Drug Free Solutions for Their Weight Management Needs alongside diet and exercise. Epitomee Medical Ltd. (TASE: EPIT), announced that the United States Food and Drug Administration (FDA) has officially ...

Scantox A/S

Scantox Group acquires Gentronix, a world leader in genetic toxicology

Ejby, Denmark (ots/PRNewswire) - Today Scantox, together with its majority owner Impilo, finalized the acquisition of Gentronix Ltd, a UK based GLP compliant genetic toxicology Contract Research Organization ("CRO"). Gentronix, now integrated into Scantox Group, is well recognized for its high-quality genetic toxicology services and strong scientific engagement, with ...

Schweizerischer Nationalfonds / Fonds national suisse

Nanoplastics put stress on trees and impair photosynthesis

Bern (ots) - Spruce and deciduous trees take up nano-sized microscopic plastic particles via their roots. These can reach the leaves and needles where they have an effect on photosynthesis. The exact mechanism behind this is not yet fully understood. It is well known that more and more plastic waste is ending up in soil and bodies of water. Researchers are particularly concerned about tiny micro- and nano-sized particles. ...

Acousia Therapeutics GmbH

Acousia Therapeutics to present its clinical Phase 2 PROHEAR study on hearing loss treatment candidate ACOU085 at upcoming conferences

Tübingen, Germany (ots) - Acousia Therapeutics GmbH, a Tübingen-based clinical stage biotech company focused on the enhancement and preservation of natural hearing, will be presenting the ACOU085 Phase 2 PROHEAR clinical study at the HansonWade 4th Inner Ear Disorders Therapeutics Summit in Boston (MA) from August ...

Grünenthal Group

Grünenthal acquires US-company Valinor Pharma and becomes global owner of Movantik®

Aachen, Germany (ots) - - Grünenthal acquires the pharmaceutical company Valinor Pharma, further strengthening Grünenthal’s footprint in the United States. - With the acquisition, Grünenthal becomes the global owner of Movantik® / Moventig® (naloxegol). - Since 2017, Grünenthal has invested more than €2 billion in successful M&A transactions, significantly ...

Schweizerischer Nationalfonds / Fonds national suisse

The tumour hacker

Soterios Pharma

Soterios Pharma Announces Positive Topline Results from Phase II Study of STS-01 in the Treatment of Mild / Moderate Alopecia Areata

London (ots/PRNewswire) - - Once-daily topical treatment of mild / moderate alopecia areata (AA) with 1% STS-01 met the primary efficacy endpoint of >30% Severity of Alopecia Tool (SALT) score improvement compared to patients receiving placebo ...

Schweizerischer Nationalfonds / Fonds national suisse

Breath analysis to monitor health status in intensive care

Medison Pharma; Alnylam Pharmaceuticals

Medison Pharma and Alnylam Pharmaceuticals Announce Expansion of their Multi-Regional Partnership in Europe and Israel to Commercialize RNAi Therapeutics in additional LATAM and APAC markets including Australia

Zug, Switzerland (ots/PRNewswire) - - The expanded partnership will allow Alnylam and Medison to help accelerate access for patients in multiple regions under one global alliance - Medison, the creator and leader of the multi-regional partnership category, will utilize its unique, unified platform for efficient ...

Norgine B.V.

Norgine B.V. submits Marketing Authorisation Application via Project Orbis for eflornithine (difluoromethylornithine [DFMO]) in high-risk neuroblastoma

Amsterdam (ots/PRNewswire) - Norgine B.V. today announced its first marketing authorisation application submissions on 10 April 2024, seeking approval for eflornithine in high-risk neuroblastoma (HRNB), via Project Orbis in Australia, Switzerland and the United Kingdom. This milestone supports Norgine's efforts to ...

Acousia Therapeutics GmbH

Acousia Therapeutics attracts new investor on its path to make hearing loss a treatable disease

Tübingen (ots) - - German pioneer biotech accelerates hearing loss solution development with fresh capital boost Acousia Therapeutics GmbH, a clinical-stage biotech company developing drug candidates against acute and chronic forms of hearing loss, proudly announces Esperante Ventures as the latest addition to its esteemed group of investors. The infusion of fresh ...

Takeda Pharma Vertrieb GmbH & Co. KG

The European Commission Approves Label Update for TAKHZYRO® (lanadelumab), Expanding Its Use to a Broader Group of Paediatric Patients with Recurrent Attacks of Hereditary Angioedema (HAE)

Zurich (ots/PRNewswire) - - TAKHZYRO® is the First Routine Prevention Treatment of HAE Approved in the EU for Patients Under the Age of Six. - The therapeutical indication for TAKHZYRO® has been extended to patients aged 2 years and older.1 - Offers a New Preventative Treatment Option for young HAE patients with ...

Medison Pharma; Ipsen

Ipsen and Medison Pharma Announce Health Canada Approval of Bylvay™ (odevixibat) for the treatment of pruritus due to Progressive Familial Intrahepatic Cholestasis (PFIC)

Zug, Switzerland and Paris (ots/PRNewswire) - Bylvay (odevixibat) is the first and only oral treatment available in Canada for the treatment of pruritus due to this rare genetic condition Today, Ipsen (Euronext: IPN) (ADR: IPSEY), a global biopharmaceutical company focused on transformative medicines in oncology, ...

Soterios Pharma

Soterios Pharma completes Phase II enrolment for STS-01 in mild / moderate (patchy) alopecia areata

London (ots/PRNewswire) - Soterios Pharma, a privately held clinical-stage pharmaceutical company, announced today that it has completed target enrolment for its Phase II trial with STS-01 for mild / moderate (patchy) alopecia areata. Final results of the study are anticipated to be available in Q2 2024. David Fleet, CEO of Soterios Pharma, said, "This represents an ...

Schweizerischer Nationalfonds / Fonds national suisse

Phosphorous - too much in lakes, too little in the soil

Bern (ots) - Over-fertilised waterways, impoverished soils: the use of phosphorous in agriculture is creating a dilemma, and it all began thousands of years ago. This has been verified by an analysis funded by the SNSF. It is well known that phosphorous from agricultural fertilisation and wastewater is harmful to lakes. But the entry of phosphorous into water is also contributing to the scarcity of this substance, which ...

MECAWARE

#Greentech: MECAWARE secures €40m to become the leader in battery recycling and the production of strategic metals in France and Europe

Lyon, France (ots/PRNewswire) - In order to speed up its industrial and commercial development, MECAWARE has secured €40 million from a pool of investors, the French government, under the auspices of the France 2030 plan, and its banking partners. This funding will enable the industrialisation of the pilot scheme ...

neustark AG

4

Neustark launches the first commercial site for permanent CO₂ storage in the EU

Takeda

Takeda Receives Positive CHMP Opinion Recommending Approval of Lanadelumab for Routine Prevention of Recurrent Attacks of Hereditary Angioedema (HAE) in Patients Aged 2 years and Older

Zurich (ots/PRNewswire) - - If Approved, Lanadelumab Will be the First Long-Term Prophylactic Treatment of HAE Available in the EU for Patients Under the Age of Six. - Positive Opinion Based on Pivotal Study SHP643-301, Evaluating the Safety Profile and Pharmacokinetics (PK) of Lanadelumab, in Combination with ...